News - Abbott Laboratories

Filter

Current filters:

Abbott Laboratories

Popular Filters

37 to 61 of 77 results

Added European indications for Abbott's Humira and Novartis' Afinitor

30-07-2012

US health care major Abbott Laboratories (NYSE: ABT) today announced that the European Commission (EC)…

Abbott LaboratoriesAfinitorAnti-Arthritics/RheumaticsEuropeHumiraNovartisOncologyPharmaceuticalRegulation

Abbott continues to see earnings growth, beating 2nd-qtr expectations

19-07-2012

US health care group Abbott Laboratories (NYSE: ABT), which is scheduled to split into two separate companies,…

Abbott LaboratoriesFinancialPharmaceutical

Five more drug majors join NIH initiative to speed therapeutic discovery

13-06-2012

Five additional pharmaceutical companies have joined a US National Institutes of Health-led effort to…

Abbott LaboratoriesBristol-Myers SquibbGlaxoSmithKlineJohnson & JohnsonNorth AmericaPharmaceuticalResearchSanofi

Roche's RoActemra beats leading rival Humira in RA study; other news from EULAR

07-06-2012

Swiss drug major Roche (ROG: SIX) yesterday released new data from the ADACTA study which showed that…

Abbott LaboratoriesAnti-Arthritics/RheumaticsHumiraPharmaceuticalResearchRoActemraRoche

Abbott Labs agrees $1.6 billion settlement over Depakote marketing practices

08-05-2012

Ending a four year investigation, US health care major Abbott Laboratories (NYSE: ABT) has reached a…

Abbott LaboratoriesDepakoteFinancialLegalMarkets & MarketingNeurologicalNorth AmericaPharmaceutical

Abbott Labs acquires drug candidate from Action Pharma

04-05-2012

US health care group Abbott Laboratories (NYSE: ABT) and Action Pharma A/S, a privately-owned company…

Abbott LaboratoriesAction PharmaLicensingNephrology and HepatologyPharmaceuticalZealand Pharma

Abbott beats forecasts as 1st-qtr sees strong sales and earnings growth

19-04-2012

US health care major Abbott Laboratories (NYSE: ABT) pleased investors yesterday, reporting better-than-expected…

Abbott LaboratoriesFinancialPharmaceutical

Abbott's Humira OKed for new ulcerative colitis indication in EU

12-04-2012

Following a previous favorable advisory committee recommendation, US health care major Abbott Laboratories…

Abbott LaboratoriesEuropeGastro-intestinalsHumiraInflammatory diseasesPharmaceuticalRegulation

AbbVie selected as name for Abbott research-based spin out

22-03-2012

Confirming its previous announcements on plans to split the US health care major, Abbott Laboratories…

Abbott LaboratoriesAbbVieMergers & AcquisitionsPharmaceutical

Gap in patent filings for biological and small-molecule drugs widening, says Withers & Rogers

20-03-2012

The number of patent applications filed by leading pharmaceutical companies for biological drugs has…

Abbott LaboratoriesBiotechnologyGlaxoSmithKlineNovartisPatentsPfizerPharmaceuticalResearchSanofi

Watson confirms Abbott Niaspan patent challenge

19-03-2012

USA-based Watson Pharmaceuticals (NYSE: WPI) has confirmed that its subsidiary, Watson Laboratories,…

Abbott LaboratoriesCardio-vascularGenericsNiaspanNorth AmericaPatentsWatson Pharmaceuticals

Abbott unit snaps up LIMS distributors

04-03-2012

As part of a series of strategic moves to build its laboratory information management system (LIMS) business…

Abbott LaboratoriesMergers & AcquisitionsPharmaceuticalSTARLIMS

Galapagos leaps on $1.35 billion RA drug deal with Abbott Labs

01-03-2012

Belgian drug developer Galapagos (Euronext: GLPG) saw its shares rocket 27% to a record high 13.89 euros…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyGalapagosLicensingPharmaceutical

EMA advisory backs Humira for UC and expanded use of Byetta

20-02-2012

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on Friday…

Abbott LaboratoriesAmylinAnti-Arthritics/RheumaticsBiotechnologyByettaDiabetesEli LillyEuropeGastro-intestinalsHumiraPharmaceuticalRegulation

Abbott on track to split; posts higher earnings

26-01-2012

Despite another challenging year for the global economy, US health care major Abbott (NYSE: ABT) again…

Abbott LaboratoriesFinancialPharmaceutical

Emergent considers options as Abbott ends drug R&D collaboration

30-12-2011

Shares of USA-based Emergent BioSolutions (NYSE: EBS) saw its shares fall 4% to $16.53 after the company…

Abbott LaboratoriesEmergent BioSolutionsLicensingOncologyPharmaceuticalResearch

Abbott in further deal with Reata

12-12-2011

US health care major Abbott Laboratories (NYSE: ABT) has entered into a second mega-million dollar licensing…

Abbott LaboratoriesAnti-Arthritics/RheumaticsbardoxoloneBiotechnologyLicensingNeurologicalPharmaceuticalReata Pharmaceuticals

Public health groups launch global campaign against Abbott Labs’ monopoly on critical AIDS medicine

11-11-2011

A global campaign to challenge US health care major Abbott Laboratories’ (NYSE: ABT) monopolistic…

Abbott LaboratoriesAnti-viralsGenericsGlobalKaletra CapsulesPharmaceuticalPricing

Litigation hits Abbott Lab’s 3rd-qtr, but shares leap as firm says it will split in two

20-10-2011

US health care major Abbott Laboratories (NYSE: ABT) saw its shares leap 10% in morning trading yesterday,…

Abbott LaboratoriesFinancialPharmaceutical

Abbott and Eisai launch of PDER drug Lipacreon in Japan

31-08-2011

Following regulatory approval earlier this year (The Pharma Letter April 27), the Japanese subsidiary…

Abbott LaboratoriesAsia-PacificEisaiGastro-intestinalsLipacreonMarkets & MarketingPharmaceutical

US FDA approves Pfizer lung cancer drug Xalkori and companion diagnostic from Abbott

30-08-2011

The US Food and Drug Administration has approved global drugs behemoth Pfizer’s (NYSE: PFE) Xalkori…

Abbott LaboratoriescrizotinibNorth AmericaOncologyPfizerPharmaceuticalRegulationXalkori

37 to 61 of 77 results

Back to top